PT  - JOURNAL ARTICLE
AU  - Boukli, Narjis
AU  - Flamand, Claude
AU  - Chea, Kim Lay
AU  - Heng, Leangyi
AU  - Keo, Seangmai
AU  - Sour, Kimhoung
AU  - In, Sophea
AU  - Chhim, Panha
AU  - Chhor, Bunthea
AU  - Kruy, Lomor
AU  - Feenstra, Jelena D M
AU  - Gandhi, Manoj
AU  - Okafor, Obiageli
AU  - Ulekliev, Camilla
AU  - Auerswald, Heidi
AU  - Horm, Viseth Srey
AU  - Karlsson, Erik A
TI  - ONE ASSAY TO TEST THEM ALL: COMPARING MULTIPLEX ASSAYS FOR EXPANSION OF RESPIRATORY VIRUS SURVEILLANCE
AID  - 10.1101/2023.01.19.23284806
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.01.19.23284806
4099  - http://medrxiv.org/content/early/2023/01/22/2023.01.19.23284806.short
4100  - http://medrxiv.org/content/early/2023/01/22/2023.01.19.23284806.full
AB  - Background Molecular multiplex assays (MPAs) for simultaneous detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza and respiratory syncytial virus (RSV) in a single RT-PCR reaction reduce time and increase efficiency to identify multiple pathogens with overlapping clinical presentation but different treatments or public health implications.Methods Clinical performance of XpertXpress® SARS-CoV-2/Flu/RSV (Cepheid, GX), TaqPath™ COVID-19, FluA/B, RSV Combo kit (Thermo Fisher Scientific, TP), and PowerChek™ SARS-CoV-2/Influenza A&B/RSV Multiplex RT-PCR kit II (KogeneBiotech, PC) was compared to individual Standards of Care (SoC). Thirteen isolates of SARS-CoV-2, human seasonal influenza, and avian influenza served to assess limit of detection (LoD). Then, positive and negative residual nasopharyngeal specimens, collected under public health surveillance and pandemic response served for evaluation. Subsequently, comparison of effectiveness was assessed.Results The three MPAs confidently detect all lineages of SARS-CoV-2 and influenza viruses. MPA-LoDs vary from 1-2 Log10 differences from SoC depending on assay and strain. Clinical evaluation resulted in overall agreement between 97% and 100%, demonstrating a high accuracy to detect all targets. Existing differences in costs, testing burden and implementation constraints influence the choice in primary or community settings.Conclusion TP, PC and GX, reliably detect SARS-CoV-2, influenza and RSV simultaneously, with reduced time-to-results and simplified workflows. MPAs have the potential to enhancediagnostics, surveillance system, and epidemic response to drive policy on prevention and control of viral respiratory infections.IMPORTANCE Viral respiratory infections represent a major burden globally, weighed down by the COVID-19 pandemic, and threatened by spillover of novel zoonotic influenza viruses. Since respiratory infections share clinical presentations, identification of the causing agent for patient care and public health measures requires laboratory testing for several pathogens, including potential zoonotic spillovers. Simultaneous detection of SARS-CoV-2, influenza, and RSV in a single RT-PCR accelerates time from sampling to diagnosis, preserve consumables, and streamline human resources to respond to other endemic or emerging pathogens. Multiplex assays have the potential to sustain and even expand surveillance systems, can utilize capacity/capability developed during the COVID-19 pandemic worldwide, thereby strengthening epidemic/pandemic preparedness, prevention, and response.Competing Interest StatementThis work was supported by Thermo Fisher Scientific, who loaned the QuantStudio 5TM RT-PCR, 96 well, 0.2 mL instrument (Applied Biosystems) and laptop to IPC for the purpose of the study, provided TaqPathTM COVID-19, FluA/B, RSV Combo Kits, and co-authors included were involved in the study design, analysis and interpretation of TaqPath results and reviewed the report.Funding StatementThis work was supported by Thermo Fisher Scientific, who loaned the QuantStudio 5TM RT-PCR, 96 well, 0.2 mL instrument (Applied Biosystems) and laptop to IPC for the purpose of the study, provided TaqPathTM COVID-19, FluA/B, RSV Combo Kits, and co-authors included were involved in the study design, analysis and interpretation of TaqPath results and reviewed the report. French Agency for Development funded the ECOMORE II project and a COVID-19 top-up (project No. CZZ 2146 01A), providing payed salary to NB for a senior medical virologist position under a temporary contract with the Institut Pasteur du Cambodge. H. A. is supported by the German Centre for International Migration and Development (CIM). Influenza, COVID-19, and RSV work at IPC and E.A.K are supported, in part, by the World Health Organization and the Food and Agriculture Association of the United Nations. COVID-19 work is supported, in part, E.A.K is funded, in part, by the Pasteur International Center for Research on Emerging Infectious Diseases (PICREID) National Institutes of Health, Department of Health and Human Services -funded project (1U01AI151758-01).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Cambodian National Ethics Committee for Health Research (No050 NECHR, 2022). Since samples were obtained as part of the national influenza surveillance system and as part of outbreak response for SARS-CoV-2, requirement for informed consent was waived for their use in the study. All samples were de-identified and the database contained no patient information.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript